Business
Currency:USD
2024/Q1
Stock NameRevenueRatio
Cystic fibrosis franchise217.43M38.28%
Other products131.51M23.15%
Evrysdi54.99M9.68%
Tremfya36.29M6.39%
Imbruvica34.97M6.16%
Trelegy33.63M5.92%
Tysabri32.72M5.76%
Other royalty income and revenues26.43M4.65%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States2.35B100.00%
